Corporate governance Annual Report on Remuneration For the year ended 31 December 2014, the Groups policy on remuneration was implemented as set out below.
Single total figure The following table shows a single total figure of remuneration in respect of qualifying services for the 2014 financial year for each ExecutiveDirector, together with comparative figures for 2013.
Further details on future salaries are available on page 97.
Benefits Hikma makes available the normal benefits in kind for executives of their level in a company of Hikmas size, such as company cars, healthcareand life insurance.
The benefits received related to school fees.
Pension This is a pension payment paid to the Hikma Pharmaceuticals Defined Contribution Retirement Benefit Plan the Benefit Plan on behalf of the Executive Directors on the same basis as other employees located in Jordan.
The Executive Directors do not receive personal pension contributions from the Group.
Under the Benefit Plan the Group matches employee contributions made, which are fixed at a maximum 5% of applicable salary.
Participants are entitled to 30% of the Groups contributions to the Benefit Plan after three years of employment with the Group, and an additional 10% in each subsequent year.
The participants interest in the Groups contribution fully vests after 10 years of employment.
The Executive Directors have served for in excess of 10 years and will receive their benefits under the scheme when they reach their 60th birthday.
Bonus During 2013, Hikma operated a cash bonus plan with a 200% of salary maximum.
In 2014, this was replaced with element A of the EIP, which has a 150% of salary maximum.
The EIP and awards made under it in respect of the 2014 performance year are described further below.
Share awards During 2013 and 2014 awards vested under the Long Term Incentive Plan LTIP which were granted in 2010 and 2011, respectively.
The LTIP operated with a 300% of salary maximum, a three-year vesting period and performance conditions based on total shareholder return and financial metrics.
Further details can be found in the 2012 report and accounts on pages 97 to 99 or on request from investors@hikma.
In 2014 the LTIP was replaced with Elements B and C of the EIP which have 150% and 100% of salary maximums, respectively.
101 Hikma Pharmaceuticals PLC Annual Report 2014 REMUNERATION REPORT continued LTIP The LTIP amount included in the 2014 single total figure of remuneration is the conditional share award granted in 2011.
The performance achieved against the performance targets is shown below.
Actual Award vested % Performance condition Weighting Threshold Maximum performance of maximum TSR 50% 50th percentile 75th percentile 60% 86% 20% of award element 100% of award element Sales growth 17% 9% 13% 20% 100% 20% of award element 100% of award element EPS growth 17% 15% 20% 12% 0% 20% of award element 100% of award element Return on invested capital 17% 10% 12% 13% 100% 20% of award element 100% of award element TSR is total shareholder return comparative performance against the Companys Comparator Group The information in the table above has been audited by Deloitte Chief Executive Return on Performance condition TSR Sales growth EPS growth invested capital Maximum number of shares capable of vesting 54,000 18,000 18,000 18,000 Percentage of maximum vesting 40% 100% 100% 100% Number of vested shares 21,762 18,000 18,000 18,000 Value of vested shares 355,156 293,760 293,760 293,760 Total value 1,236,436 $2,085,993 Share price on vesting was 16.32 and there were $0.594 to 1 The information in the table above has been audited by Deloitte Vice Chairman Return on Performance condition TSR Sales growth EPS growth invested capital Maximum number of shares capable of vesting 36,000 12,000 12,000 12,000 Percentage of maximum vesting 40% 100% 100% 100% Number of vested shares 14,508 12,000 12,000 12,000 Value of vested shares 236,771 195,840 195,840 195,840 Total value 824,291 $1,390,662 Share price on vesting was 16.32 and there were 0.594 to $1 The information in the table above has been audited by Deloitte 102 Corporate governance Executive Incentive Plan The EIP was approved by shareholders at the 2014 AGM and isthe sole incentive arrangement for Executive Directors.
The EIP is composed ofthree elements: Maximum award % of salary Pay-out mechanism Vesting period Risks after award Additional requirements A 150% Cash bonus Immediate None None B 150% Deferred shares 2 years f Forfeiture clawback f Share price 50% of the total share award is subject f Employed to a holding period after vesting.
These shares may not be sold until C 100% Restricted shares 3 years f Clawback fiveyears after grant.
f Share price f Employed The level of award made under the EIP depends on the achievement of performance conditions: f 50% Profit Before Tax f 40% Strategic and Operational Targets sub-conditions apply f 10% Personal Targets sub-conditions apply The following table sets out the performance conditions and targets for 2014 and their level of satisfaction: Said % Mazen % Basis of measurement Threshold Target Max Results Achievement of salary of salary PROFIT BEFORE f Budget $212m PBT $235m PBT $259m PBT $362m PBT versus budget of Max 200% 200% TAX PBT $235m PBT 154% of budget STRATEGIC AND f Maximising 5% revenue 0% revenue 5% revenue Group revenue growth of Max 20% 20% portfolio growth growth growth 9% in 2014 on top of the OPERATIONAL opportunities exceptional performance TARGETS in 2013 Significant expansion of oral generic and injectables in US 100 new 150 new 200 new 263 new product approvals Max 40% 40% f Strengthening product product product and broadening approvals approvals approvals our product portfolio Maintain quality Maintain and Significantly Excellent quality record Max 20% 20% f Maintaining high base improve quality enhance quality and Acquired significant new high base quality and efficient quality equipment that is manufacturing manufacturing being transferred to existing base facilities to fully approved facilities maximise profitability f Investing for 12% ROIC 15% ROIC 20% ROIC Our disciplined capital Max 40% 20% growth investment approach held ROIC to 23% f Developing a Some people Significant Maximise 100 management employees Max 20% 40% highly skilled, development people people undertook a mini MBA effective and development development 12% increase in diverse workforce female management 15% increase in international assignees 55 new product 65 new product 75 new product 75 new product Max 20% 20% f Ensuring marketing marketing marketing marketing launches sustainable longlaunches launches launches term growth 103 Hikma Pharmaceuticals PLC Annual Report 2014 REMUNERATION REPORT continued Said % Mazen % Basis of measurement Threshold Target Max Results Achievement of salary of salary PERSONAL Not Not Not Implemented changes arising Max 40% 40% f Hikma culture quantifiable quantifiable quantifiable from the first employee Personal satisfaction survey development Employee Updated and expanded the satisfaction Code of Conduct to seven functional languages Achieved certain personal development targets set bythe Remuneration Committee and Board TOTAL Max 400% 400% In accordance with the EIP rules, the following awards have been made in respect of the 2014 performance year: Maximum potential Level of Value of Executive EIP Element Salary % of salary satisfaction bonus shares Receive Additional Chairman and A Cash Bonus $842,265 150% 100% $1,263,398 Cash now March 2015 None Chief Executive B Deferred Shares 150% $1,263,398 Shares in 2 years 50% of total shares unsaleable until five from May 2015 years after grant C Restricted Shares 100% $842,265 Shares in 3 years from May 2015 Vice Chairman $620,172 100% A Cash Bonus 150% $930,258 Cash now March 2015 None 50% of total shares B Deferred Shares 150% $930,258 Shares in 2 years unsaleable until five from May 2015 years after grant C Restricted Shares 100% $620,172 Shares in 3 years from May 2015 The information in the table above has been audited by Deloitte Note: Elements B and C will be granted on 15 May 2015, subject to approval at the AGM.
Subject to meeting the vesting criteria, these elements will be disclosed as remuneration received in the years 2017 and 2018, respectively.
This is consistent with the methodology used throughout this report and previously Non-Executive Directors The Non-Executive Directors earned the following fees during the year under review and the prior year these figures have been pro-rated fortime served in the relevant position : 2013 2014 Taxable Taxable Total fee Accommodation Total Total fee Accommodation Total Name Position 000 000 000 000 000 000 Robert Pickering Senior Independent Director 83.5 2.2 85.7 91.6 2.2 93.8 Breffni Byrne Audit Committee Chairman 98.5 10.4 108.9 102.5 4.3 106.8 Michael Ashton Remuneration Committee Chairman 91.0 12.3 103.3 95.0 8.1 103.1 Ali Al-Husry Non-Executive Director 76.0 0.0 76.0 80.0 0.0 80.0 Ronald Goode CRE Committee Chairman 91.0 12.8 103.8 95.0 7.6 102.6 Pat Butler Audit Committee Chairman Designate 0.0 0.0 0.0 58.3 0.0 58.3 Dr Pamela Kirby Independent Director 0.0 0.0 0.0 7.3 0.0 7.3 Samih Darwazah Chairman retired 157.5 0.0 157.5 91.7 0.0 91.7 Sir David Rowe-Ham Senior Independent Director retired 91.0 0.0 91.0 43.5 0.0 43.5 Note: Taxable Accommodation refers to certain accommodation expenses for Non-Executive Directors that are wholly related to their attendance at Board meetings and are in accordance with normal Hikma expense policy.
These expenses are treated as a taxable benefit by the UK authorities and the above figure includes the corresponding tax contribution The information in the table above has been audited by Deloitte 104 Corporate governance Payments to past Directors and for loss of office There were no payments to past Directors and no payments for loss of office during the financial year.
Outstanding share awards Sales EPS TSR ROIC TOTAL growth growth 2012 LTIP GRANT 50.0% 16.7% 16.7% 16.7% 100.0% 2013 LTIP GRANT 49.0% 16.7% 16.7% 16.7% 98.9% 2014 LTIP GRANT 50.0% 3.3% 0.0% 16.7% 70.0% In respect of each of the Executive Directors, the aggregate number of shares outstanding at the year end under option was: Director Shares max Type of interest Basis of award Exercise price Date of award Date of vesting Face value Said Darwazah 97,000 Conditional award 150% salary Nil 18 May 2012 18 May 2015 $2,087,099 102,000 Conditional award 187% salary Nil 16 May 2013 16 May 2016 $3,102,155 63,000 Conditional award 200% salary Nil 16 May 2014 16 May 2017 $1,936,373 Total 262,000 2013: 307,000 Mazen Darwazah 65,000 Conditional award 150% salary Nil 18 May 2012 13 May 2015 $1,398,571 53,000 Conditional award 140% salary Nil 16 May 2013 18 May 2016 $1,611,904 46,000 Conditional award 200% salary Nil 16 May 2014 16 May 2017 $1,413,860 Total 164,000 2013: 190,000 The face value is calculated using the vesting percentages described earlier in this section and the share price of 19.79 and foreign exchange rates of $0.64374 to 1 on 31 December 2014.
The information in the table above has been audited by Deloitte 105 Hikma Pharmaceuticals PLC Annual Report 2014 REMUNERATION REPORT continued It should be noted that the real value received by Executive Directors under the share incentive arrangements is dependent upon satisfaction ofperformance conditions and the share price of Hikma at that time.
The applicable share prices for Hikma during the period under review were: Market price Closing price 1 January 2014 1,197.5p 31 December 2014 1,979.0p 2014 Range low to high 1,170.62p to 2,072.0p 10 March 2015 2,136.0p The information in the table above has been audited by Deloitte Dilution In accordance with the guidelines set out by the Investment Association of British Insurers, Hikma can issue a maximum of 10% of its issued share capital in a rolling 10-year period to employees under all its share plans and a maximum of 5% of this 10% for discretionary share plans.
The following table summarises the current level of dilution resulting from Company share plans following the Listing of Hikma in 2005: Granted in a rolling Granted during Type of Plan 10-year period the year Discretionary Share Plans 5% Limit 4.37% 0.35% Share ownership The Committee believes that its share ownership policy strongly links executive and shareholders interests.
All Executive Directors are required to build and maintain a minimum shareholding equal to three times base salary.
The limits under and compliance with this policy are reviewed periodically by the Committee.
The table below demonstrates that the target shareholdings as a percentage of salary were met in full by the Executive Directors.
Requirement Executive Director Target Actual fulfilled?
Said Darwazah 300% 295x Yes Mazen Darwazah 300% 293x Yes The information in the table above has been audited by Deloitte Share ownership requirements also apply to Hikma executive management who are required to build and maintain a minimum shareholding equal to at least two times base salary.
In certain cases the shareholding requirement has been increased in order to reflect local executive remuneration practice.
Executive managements shareholdings as a percentage of salary were: Requirement Date Requirement Lowest Highest Average Total shares fulfilled?
9 March 2015 200% 395% 2,578% 1,289% 1,020,961 Yes 11 March 2014 200% 224% 2,236% 1,071% 954,607 Yes The information in the table above has been audited by Deloitte Compliance with the shareholding requirement is measured annually at the time of this report.
Should executives have an insufficient number of shares, any options vesting under any Hikma share scheme will be retained in a nominee facility which is managed by Hikma.
The executive will receive dividends but will not be able to dispose of his her shares until the requirement is met and then only to the extent ofshares inexcess of the requirement.
106 Corporate governance Director share interests Said Darwazah, Mazen Darwazah and Ali Al-Husry are Directors and shareholders of Darhold Limited.
Darhold Limited holds 57,183,028 ordinary shares of Hikma.
The table below breaks down their shareholding in Hikma by shares effectively owned through Darhold and shares held personally.
Holding in own Total Director % of Darhold of Hikma shares name Nominee shareholding Said Darwazah 18.90% 10,807,592 190,000 10,997,592 Mazen Darwazah 9.52% 5,443,824 695,225 6,139,049 Ali Al Husry 7.00% 4,002,812 1,109,748 5,112,560 The information in the table above has been audited by Deloitte The following table sets out details of the Directors shareholdings and, where there are shareholding requirements, whether these have been met: Number of shares Total number Share ownership owned outright Conditional of shares requirements Number of shares including shares or interests Name % of salary required to hold connected persons under the LTIP in shares Said Darwazah 300% 115,864 10,997,592 262,000 11,375,456 Mazen Darwazah 300% 65,269 6,139,049 164,000 6,368,318 Robert Pickering 7,500 7,500 Breffni Byrne 10,000 10,000 Michael Ashton 18,566 18,566 Ali Al-Husry 5,112,560 5,112,560 Ronald Goode 10,000 10,000 Pat Butler 1,375 1,375 Dr Pamela Kirby 0 0 The information in the table above has been audited by Deloitte.
The share price used to calculate whether the shareholding requirements have been met is the price on 9 March 2015 of23.31 and foreign exchange rates of $0.66451 to 1 on the same date The following table sets out details of the Directors shareholdings and performance measures that apply to those holdings: Shares Options With With performance performance Vested Exercised Name measures Without measures Without but unexercised During year Said Darwazah 10,997,592 115,864 75,924 Mazen Darwazah 6,139,049 65,269 50,616 Robert Pickering 7,500 Breffni Byrne 10,000 Michael Ashton 18,566 Ali Al-Husry 5,112,560 Ronald Goode 10,000 Pat Butler 1,375 Dr Pamela Kirby 0 The information in the table above has been audited by Deloitte Ali Al Husry holds his shares in Hikma and Darhold Limited through a vehicle called DYKB Limited The information in the table above has been audited by Deloitte.
The share price used to calculate whether the shareholding requirements have been met is the price on 9 March 2015 of23.31 and foreign exchange rates of $0.66451 to 1 on the same date 107 Hikma Pharmaceuticals PLC Annual Report 2014 REMUNERATION REPORT continued Remuneration table and performance graph The following table sets out the total remuneration and amounts vesting under short term and long term incentive plans for the same period in respect of the Directors holding the positions of Chief Executive and Vice Chairman.
TOTAL SHAREHOLDER RETURN SINCE IPO % 800 700 672% 600 HIKMA PHARMACEUTICALS PLC 500 FTSE 350 PHARMACEUTICALS & 400 BIOTECHNOLOGY SEC 300 200 100 0 FTSE 250 -100 DEC 05 DEC 06 DEC 07 DEC 08 DEC 09 DEC 10 DEC 11 DEC 12 DEC 13 DEC 14 CEO and average employee change The table below shows how the percentage change in the Chief Executives CEOs salary, benefits and bonus between 2013 and 2014 compares with the percentage change in the average of each of those components of pay for employees.
Salary Bonus Percentage Percentage 2014 2013 increase 2014 2013 increase CEO $842,265 $802,500 4.7% $1,263,398 $1,605,000 27.0% Employees $m 178 160 10.1% 47.1 44.6 5.3% Number of employees 7,139 7,067 1.0% 7,139 7,067 1.0% Average per employee $24,933 $22,640 9.2% $6,598 $6,311 4.3% The information in the table above has been audited by Deloitte The Groups pay review which took effect from 1 January 2014 awarded average percentage increases in wages and salaries of 9% forexisting employees.
The nature and level of benefits to employees in the year ended 31 December 2014 was broadly similar to that in theprevious year.
The total amount of bonuses paid to employees excluding the Executive Directors in respect of the year ended 31 December 2014 was 4% higher than in 2013.
Relative importance of spend on pay The following table sets out the total amount spent in 2014 and 2013 on remuneration of the Groups employees and major distributions to shareholders.
